Aims: Cladribine tablets have shown significant efficacy for the treatment of relapsing multiple sclerosis, a chronic and debilitating immune-mediated disorder. This study was conducted to examine acute and/or cumulative effects of cladribine tablets 10 mg (3.5 or 5.25 mg/kg cumulative dose over 2 years) on heart rate, AV conduction and cardiac repolarization in patients with relapsing-remitting multiple sclerosis (RRMS).
| INTRODUCTION
Multiple sclerosis (MS) is a chronic and debilitating immune-mediated disorder of the central nervous system, in which B and T cells are believed to play a major pathophysiological role. 1 Cladribine tablets 10 mg (MAVENCLAD ® ) were recently approved in Europe 2 and other regions for the treatment of adults with relapsing MS (RMS), and were shown to have significant efficacy for the treatment of RMS in placebo-controlled Phase III trials. 1, 3, 4 Cladribine is a nucleoside analogue of deoxyadenosine. The cladribine prodrug is phosphorylated intracellularly to its active product, 2-chlorodeoxyadenosine triphosphate (Cd-ATP), primarily by deoxycytidine kinase. In most cells this deoxynucleotide product is degraded, by 5'-nucleotidase. Cells containing a high deoxycytidine kinase to 5′-nucleotidase activity ratio such as B and T lymphocytes accumulate deoxynucleotides to toxic concentrations, resulting in cell death. By this mechanism, cladribine tablets exert a selective mode of action on B and T lymphocytes. 5, 6 Assessing the potential for a new drug to affect cardiac ventricular repolarization, thereby causing life-threatening arrhythmias, is now an integral component of premarketing safety assessment in preclinical and clinical development.
The ICH E14 Guideline recommends a "Thorough QT Study"
(TQT) as a default approach to assess clinical QT risk. 7 TQT studies aim for careful evaluation of drug effects on ventricular repolarization (i.e. the electrocardiographic QT/QTc interval) at multiples of therapeutic exposure together with a positive control to confirm the sensitivity of the study and methods employed. Yet for some drugs and diseases, including oncology and immunosuppressive drugs, elements of the TQT may be impractical or unethical (e.g. studies in healthy volunteers and administration of supra-therapeutic doses) due to the potential for posing unacceptable risk to healthy volunteers. 8, 9 In these instances, alternative approaches to QT/QTc risk assessment are needed, and must be carefully considered and pur- 
| ECG substudy of CLARITY
The ECG substudy in the target population of RRMS patients was designed to evaluate potential acute and/or cumulative effects of cladribine on the ECG intervals (RR, PR, QRS, QT, QTcB and QTcF) and T-wave morphology, with a particular emphasis on the heart rate corrected QT interval (QTcF, QTcB), as a well-accepted surrogate measure signifying delay or heterogeneity in cardiac ventricular repolarization which may possibly be associated with proarrhythmic characteristics of a drug. QTcF was the primary outcome variable. The timing of the ECG assessments within a day (between 0.5 and 3 hours after drug administration) and the day within a treatment week (Day 1) was selected to obtain ECGs at maximum exposure and to allow for
proper characterization of the concentration-effect relationship. To allow for a concentration-effect analysis of QT/QTc-interval data (QTc/PK modelling), the entire ECG population (n = 135) formed part of the PK sub-population (n = 173) of the CLARITY study.
| ECG data collection
For the ECG substudy, 23 centres from nine countries were appropriately qualified, equipped and quality checked by a dedicated vendor, and central reading of all ECGs by expert cardiologists was applied (eResearchTechnology, Inc., Philadelphia, PA, USA).
Standard 12-lead ECGs were recorded at the study sites in patients randomized to the ECG population. These patients had ECGs collected at pre-study evaluation, study Day 1 and at Weeks 5, 9, 13, 48 and 52 at the following time points: three ECGs taken 15 minutes apart pre-dose, and two ECGs taken no longer than five minutes apart between 0.5 and 3 hours post-dosing. Recordings were made on Day 1 of each treatment week in each patient after at least 15 minutes' rest in the supine position. According to the ECG substudy protocol, a total of 31 ECGs (i.e., three baseline and two post-dose ECGs at each visit, plus one screening ECG) were to be recorded for each patient.
The timing of the ECG assessments within a day (between 0.5 and 3 hours after drug administration) and the day within a week (Day 1) was selected to obtain ECGs at maximum cladribine exposure and to allow for proper characterization of the concentration-effect relationship. Instead of pre-specifying a fixed post-dose time, a target time window of 0.5-3 hours post-dose was specified for random ECG assessments. This time window was selected because it covers the times of the expected C max values of the population as well as the initial decline in plasma concentrations, which is important to allow for the characterization of the concentration-effect. The sampling strategy of capturing ECGs at random times within a pre-specified time window, also had the additional methodological advantage that ECGs in individual patients were captured at different post-dose times at each occasion of the six different study visits. Hence, this approach provided a set of six "serial" post-dose ECGs in each individual patient, that were obtained at random times within 0.5 and 3.0 hours postdose, essentially following a "population approach" that is well accepted for PK analysis. The following calculations were made from the interval measurements: Heart rate (HR = 60/RR); heart rate corrected QT-interval using HR-correction by Fridericia's formula (QTcF = QT/3√RR); heart rate corrected QT-interval using HR-correction by Bazett's formula The primary outcome variable, the HR correction according to Fridericia (QTcF) was pre-specified in the study protocol. Use of an alpha parameter to account for individual HR correction (e.g., Friberg et al. 2006 11 ) was explored based on the placebo data. Since there was no apparent improvement in describing the data with this approach, and inter-subject variability in alpha was not supported, QTcF was used as the dependent variable in the analysis.
| ECG procedures and analysis

| Pharmacokinetic assessments
To allow for a concentration-effect analysis of QT/QTc-interval data (QTc/PK modelling), the patients who underwent ECG recording also took part in a pharmacokinetic substudy. Blood samples for quantification of cladribine and major cladribine metabolite (2-chloroadenine; M1) plasma concentrations were taken following a population pharmacokinetic (PopPK) approach. Samples were taken on the first day of the first treatment week in Year 2, with a first sample taken between 1 and 6 hours after dosing and a second sample 24 hours post dose, prior to intake of the dose on Day 2 of the respective treatment week. Further details on the PopPK analysis were published by Savic et al. 12 Plasma concentrations were determined using a validated HPLC-MS/MS with a lower limit of quantitation (LLOQ) of 0.1 ng/mL for cladribine and for 2-chloroadenine (M1), respectively.
| Statistical analysis
All ECG interval parameters are presented as arithmetic means of two baseline >30 ms and >60 ms; QT interval >500 ms; PQ interval >200 ms; QRS interval >120 ms; HR <50 or >100 beats per minute (bpm) (bradycardia); HR >100 bpm (tachycardia).
In addition, linear regression analyses according to Garnett et al. 13 and a modelling and simulation data analysis applying a population approach using NONMEM were conducted to analyse the individual across visits. Figure 2A shows modelled cladribine plasma concentration-time profiles of the ECG/PK substudy population from the PopPK analysis, Figure 2B shows the modelled distribution of the times of maximum cladribine plasma concentrations (t max ) in the ECG/PK substudy population, and Figure 2C displays the actual distribution of the times of capturing post-dose ECG data. Overall, the distribution of t max data and ECG collection times were very consistent.
| Heart rate
The mean placebo-corrected change from baseline for the cladribine 3.5 mg/kg and 5.25 mg/kg groups was −1.6 bpm and −1.5 bpm,
respectively. There were no significant imbalances in either the bradycardic or tachycardic outliers compared with placebo.
| PR-and QRS-interval duration
The mean placebo-corrected change in PR interval duration from baseline was 3 ms for both the cladribine 3.5 mg/kg and 5.25 mg/kg groups which is of no clinical significance. There was a slight increase in the number of outliers in the 5.25 mg/kg dose group; in that group 1-4 patients per visit showed PR interval duration of >200 ms vs. no patients in the placebo group and one patient in the cladribine 3.5 mg/kg group.
The mean placebo-corrected change in QRS interval duration from baseline was 0 ms and 1 ms for the cladribine 3.5 mg/kg and 5.25 mg/kg dose groups, respectively; there was one outlier (QRS > 120 ms) in the 5.25 mg/kg dose group, and no outlier patients in the placebo and cladribine 3.5 mg/kg groups.
| Analyses of central QTcF tendencies
Comparison of mean visit baseline QTcF values vs. post-dose placeboadjusted QTcF data (i.e., ΔQTcF) did not show remarkable post-dose
QTcF differences for either of the cladribine treatment groups compared with baseline. At several visits and across all treatment groups including the placebo group, there were consistently minor, transient 
SD, standard deviation.
and clinically insignificant mean post-dose QTcF increases between 1 and 4 ms vs. QTcF visit baseline. However, the point estimates and the upper limits of 90% CI for placebo-corrected post-dose QTcF changes from visit baseline were at all occasions and for both cladribine treatment groups less than 5 ms (point estimates) and less than 7 ms (upper limit one-sided of 90% CI), respectively. These results are illustrated in Figure 3 .
Placebo-adjusted ANOVA results (point estimates and 90% CI) for the time averaged QTcF changes from visit baseline are summarized for all study visits and both cladribine treatments in Table 2 . These data indicate lack of a clinically relevant acute QTcF prolongation by both employed oral cladribine treatments. The findings were consistent across visits over the entire trial duration.
Placebo-adjusted ANOVA results (point estimates and 90% CI) for the differences to placebo of QTcF changes from study baseline are summarized for all study visits and both doses of cladribine in Table 3 . In the cladribine 3.5 mg/kg treatment group, post-dose QTcF increases were below 6 ms at all time points, and less than 3.2 ms at five of the six visits ( Table 3) . The upper 90% CI data were below 8.2 ms at five of the six visits, and below 11.5 ms at one visit (Week 48). There was no apparent monotonic time-effect over the study duration.
In the cladribine 5.25 mg/kg treatment group, however, there was a non-clinically significant potential time-effect noted with more dis- 
| Categorical QTcF outlier analyses
No evident outlier incidents were noted in any of the treatment groups, which include absolute QT duration >500 ms, QTcF duration >500 ms, QTcF duration >480 ms, a >60 ms change from study or visit baseline QTcF, and findings of abnormal U waves. 
| T-and U-wave morphology changes
The morphological changes upon both cladribine treatment dose regimens did not show any significant changes in T-or U-wave morphology compared with visit or study baseline ECGs, and no differences compared with placebo. A single patient in the cladribine 3.5 mg/kg group showed an inverted T-wave on three occasions (Weeks 1, 5 and 9).
| Population PK/PD modelling and simulation analysis
The results of the PK/QTcF modelling and simulation analysis were overall highly consistent with the results of the standard descriptive and ANOVA data analyses by treatment groups as detailed above.
The pre-dose QTcF was estimated to be 405 ms for women and 385 ms for men. The inter-individual and inter-occasion variability (expressed as coefficients of variation) in the baseline QTcF were estimated to be 3.5% and 1.7%, respectively, and the additive residual 
| Correlation of cladribine plasma concentration and QTcF
Available cladribine plasma concentration data and QTcF interval data were subjected to two different linear regression analyses by using QTcF study and visit baseline data. For the analyses, all observations with a time difference of less than 1 hour between PK sampling and ECG assessment were included, and the correlation between the placebo-adjusted post-dose QTcF differences to baseline QTcF (ΔΔQTcF) with the corresponding cladribine plasma concentrations was analysed according to the approach proposed by Garnett et al. 13 For the placebo adjustment, the mean of the post-dose QTcF values within the placebo group was calculated for each visit. The analysis was performed by using both study and visit baselines. The results of both analyses are highly consistent and illustrated in Figure 4 for the study baseline analysis, and Hermann et al. 16 for the visit baseline analysis.
Both These are defined by the International Conference on Harmonisation (ICH) Guidelines SB7 (preclinical) and E14 (clinical). 7, 20 Guideline ICH E14 describes the clinical evaluation of drug-induced QTc prolongation via a well-controlled clinical study, the TQT study, typically conducted in healthy volunteers with employment of supra-therapeutic doses and positive control treatments, as the primary method of
Cladribine plasma concentration vs. ΔΔQTcF using study baseline in the ECG/ PK subpopulation of the CLARITY trial. ECG, electrocardiogram; PK, pharmacokinetic evaluating the QT liability of NCEs during their development. As science develops, these guidelines become subject to updates and amendments such as the recently issued Q&A document R3 to the ICH E14 Guideline. 10 Therein it is acknowledged that in certain cases conventional TQT studies might not be feasible, and suggests a variety of study design and data analysis considerations-including concentration effect analyses and modelling-to address the clinical development needs for cardiac safety testing in such cases. The intense ECG substudy of cladribine tablets presented here applied many of the suggested methodological approaches of ICH E14 (R3) before the document was issued.
Repeat-dose TQT studies in healthy subjects were conducted for other recently approved orally acting RMS disease-modifying drugs with shorter duration of immune-suppressive effects, such as fingolimod and teriflunomide. While the teriflunomide TQT study did not show potential for prolonging the QTcF interval at mean therapeutic steady-state concentrations compared with placebo, 21 with fingolimod a mild QTc prolongation was seen in a dedicated TQT study. 22 T lymphocytes which goes along with a long-lasting reduction in lymphocyte count. 5, 6 Given this mode of action, the examination of cardiac safety by means of a TQT study was not feasible. Therefore, an intense ECG substudy as part of a multinational, large-scale Phase III study (the CLARITY trial) has been designed as an alternative approach to detect and characterize possible drug effects on the QT/QTc interval of the ECG. Such an alternative approach has also been suggested by others. 8, 9 The data collection in the intense ECG substudy applied important methodological prerequisites to enable accurate measurement and quantification of the time intervals of the ECGs. These measures included appropriately qualified and trained personnel at selected study centres, validated 12-lead ECG machines provided, maintained and quality checked by a dedicated vendor, replicate ECG collection Another aspect of this design feature is that this approach was associated with minimal discomfort and PK sampling burden of the patients, but allowed ECG and PK collection over a wide range of plasma concentrations despite the low sampling burden.
As shown in Figure 4 , a broad range of cladribine plasma concentra- (Table 2 ). For the 3.5 mg/kg cladribine group, the same holds true for the comparisons to study baseline, with the exception of a single occasion slightly above these limits (Week 48 with mean QTcF of 5.99 ms and a corresponding 90% CI of 11.44 ms; Table 3 ). These results are confirmed by the linear regression concentration-effect analysis of ΔΔQTcF according to Garnett et al. 13 ( Figure 4 and Hermann et al. 16 ), which indicate that there is no significant correlation between the placebo-adjusted post-dose QTcF interval duration and cladribine plasma concentrations regardless of whether study or visit baseline comparisons are considered. 
| CONCLUSIONS
In conclusion, the ECG results presented here indicate that cladribine showed no evidence of any effect on heart rate, AV conduction or cardiac depolarization as measured by the PR and QRS interval durations.
No significant changes in T-wave morphology were observed in either of the cladribine treatment groups.
Overall, the data showed no evidence of an acute cladribine concentration-dependent effect on cardiac repolarization. Considering the challenges associated with the long duration of the trial, and the possible contributing factors of the subjects' underlying condition, the QTcF outcomes were found to be highly consistent over time vs.
visit baseline data, indicating that cladribine does not confer a clinically meaningful long-term effect on cardiac repolarization. Considering the recent marketing approval of cladribine tablets for MS in Europe and other regions, and the up-to-date assessment methodology used for cardiac safety evaluation, this report is highly relevant for the practising community, and also to clinical researchers involved in cardiac safety testing of novel products.
